Sarepta Therapeutics Inc (NASDAQ:SRPT) Director Richard Barry Buys 5,000 Shares

Sarepta Therapeutics Inc (NASDAQ:SRPT) Director Richard Barry purchased 5,000 shares of the stock in a transaction dated Friday, September 13th. The stock was purchased at an average cost of $87.49 per share, for a total transaction of $437,450.00. Following the completion of the purchase, the director now directly owns 3,183,756 shares of the company’s stock, valued at $278,546,812.44. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Richard Barry also recently made the following trade(s):

  • On Tuesday, August 20th, Richard Barry purchased 5,000 shares of Sarepta Therapeutics stock. The stock was purchased at an average cost of $99.32 per share, for a total transaction of $496,600.00.
  • On Wednesday, August 14th, Richard Barry purchased 3,700 shares of Sarepta Therapeutics stock. The stock was purchased at an average cost of $122.50 per share, for a total transaction of $453,250.00.
  • On Monday, August 12th, Richard Barry purchased 1,300 shares of Sarepta Therapeutics stock. The stock was purchased at an average cost of $122.50 per share, for a total transaction of $159,250.00.

NASDAQ:SRPT opened at $83.67 on Thursday. Sarepta Therapeutics Inc has a 52 week low of $81.33 and a 52 week high of $165.87. The company has a quick ratio of 7.84, a current ratio of 8.81 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $6.39 billion, a P/E ratio of -15.32 and a beta of 2.20. The stock’s fifty day moving average is $108.26 and its two-hundred day moving average is $124.00.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, August 7th. The biotechnology company reported ($3.74) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.08) by ($2.66). Sarepta Therapeutics had a negative net margin of 165.52% and a negative return on equity of 55.37%. The business had revenue of $94.67 million during the quarter, compared to analysts’ expectations of $91.05 million. During the same quarter in the prior year, the firm earned ($1.67) EPS. Sarepta Therapeutics’s revenue for the quarter was up 28.8% compared to the same quarter last year. Sell-side analysts anticipate that Sarepta Therapeutics Inc will post -4.94 earnings per share for the current fiscal year.

A number of large investors have recently bought and sold shares of SRPT. Evolution Wealth Advisors LLC purchased a new stake in Sarepta Therapeutics in the second quarter valued at $25,000. Trust Co. of Vermont raised its position in Sarepta Therapeutics by 2,125.0% in the second quarter. Trust Co. of Vermont now owns 178 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 170 shares during the period. Steward Partners Investment Advisory LLC purchased a new stake in Sarepta Therapeutics in the second quarter valued at $32,000. BSW Wealth Partners purchased a new stake in Sarepta Therapeutics in the second quarter valued at $52,000. Finally, Coastal Investment Advisors Inc. raised its position in Sarepta Therapeutics by 57.4% in the second quarter. Coastal Investment Advisors Inc. now owns 425 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 155 shares during the period. Institutional investors own 95.08% of the company’s stock.

A number of analysts have recently issued reports on the company. Evercore ISI reaffirmed a “buy” rating and issued a $200.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, August 8th. Bank of America lowered their price objective on Sarepta Therapeutics from $200.00 to $189.00 and set a “buy” rating on the stock in a research note on Tuesday, August 20th. Royal Bank of Canada lowered their price objective on Sarepta Therapeutics to $204.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 20th. Cantor Fitzgerald lowered their price objective on Sarepta Therapeutics from $231.00 to $175.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 20th. Finally, Credit Suisse Group lowered their price objective on Sarepta Therapeutics from $207.00 to $201.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 20th. One investment analyst has rated the stock with a sell rating, twenty-one have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $191.83.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.

See Also: Net Margin

Insider Buying and Selling by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.